1. Sequence, 'subtle' alternative splicing and expression of the CYYR1 (cysteine/tyrosine-rich 1) mRNA in human neuroendocrine tumors
- Author
-
Silvia Canaider, Federica Facchin, Flavia Frabetti, Paolo Carinci, Shane Huntsman, Raffaella Casadei, Maria Zannotti, Domenico Coppola, Pierluigi Strippoli, Lorenza Vitale, Luca Lenzi, Vitale L., Frabetti F., Huntsman S. A., Canaider S., Casadei R., Lenzi L., Facchin F., Carinci P., Zannotti M., Coppola D., and Strippoli P.
- Subjects
Adult ,Male ,Cancer Research ,Pan troglodytes ,Molecular Sequence Data ,Sequence Homology ,Sequence alignment ,Biology ,Digestive System Neoplasms ,Polymorphism, Single Nucleotide ,lcsh:RC254-282 ,Evolution, Molecular ,Species Specificity ,Neoplasms ,Genetics ,Animals ,Humans ,Point Mutation ,Protein Isoforms ,Amino Acid Sequence ,RNA, Messenger ,RNA, Neoplasm ,Codon ,Gene ,Peptide sequence ,Aged ,Expressed sequence tag ,Messenger RNA ,Alanine ,Base Sequence ,Reverse Transcriptase Polymerase Chain Reaction ,Alternative splicing ,HUMAN ,Membrane Proteins ,Middle Aged ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Molecular biology ,Gene Expression Regulation, Neoplastic ,Alternative Splicing ,Neuroendocrine Tumors ,Oncology ,RNA splicing ,Female ,Chromosome 21 ,GENOMICS ,Sequence Alignment ,Research Article - Abstract
Background CYYR1 is a recently identified gene located on human chromosome 21 whose product has no similarity to any known protein and is of unknown function. Analysis of expressed sequence tags (ESTs) have revealed high human CYYR1 expression in cells belonging to the diffuse neuroendocrine system (DNES). These cells may be the origin of neuroendocrine (NE) tumors. The aim of this study was to conduct an initial analysis of sequence, splicing and expression of the CYYR1 mRNA in human NE tumors. Methods The CYYR1 mRNA coding sequence (CDS) was studied in 32 NE tumors by RT-PCR and sequence analysis. A subtle alternative splicing was identified generating two isoforms of CYYR1 mRNA differing in terms of the absence (CAG- isoform, the first described mRNA for CYYR1 locus) or the presence (CAG+ isoform) of a CAG codon. When present, this specific codon determines the presence of an alanine residue, at the exon 3/exon 4 junction of the CYYR1 mRNA. The two mRNA isoform amounts were determined by quantitative relative RT-PCR in 29 NE tumors, 2 non-neuroendocrine tumors and 10 normal tissues. A bioinformatic analysis was performed to search for the existence of the two CYYR1 isoforms in other species. Results The CYYR1 CDS did not show differences compared to the reference sequence in any of the samples, with the exception of an NE tumor arising in the neck region. Sequence analysis of this tumor identified a change in the CDS 333 position (T instead of C), leading to the amino acid mutation P111S. NE tumor samples showed no significant difference in either CYYR1 CAG- or CAG+ isoform expression compared to control tissues. CYYR1 CAG- isoform was significantly more expressed than CAG+ isoform in NE tumors as well as in control samples investigated. Bioinformatic analysis revealed that only the genomic sequence of Pan troglodytes CYYR1 is consistent with the possible existence of the two described mRNA isoforms. Conclusion A new "subtle" splicing isoform (CAG+) of CYYR1 mRNA, the sequence and the expression of this gene were defined in a large series of NE tumors.
- Published
- 2007